Novo Nordisk just put $300 million on the table. The company secured exclusive global rights to Hengrui Pharma’s HRS-1596, a new oral GLP-1/GIP dual agonist. The deal could reach $2.6 billion if every milestone is hit. This is a big bet on a once-weekly oral drug for type 2 diabetes and weight management. Novo wants to change the game for patients who need easier dosing.
The oral GLP-1 field is getting crowded. Novo’s move shows it wants to stay ahead. HRS-1596 is now in Phase 1 trials in China. The drug targets both GLP-1 and GIP receptors. The goal is better blood sugar control and weight loss. But it’s early. No one knows yet if it works or is safe.
Hengrui Pharma received regulatory clearance in China to begin Phase 1 trials of HRS-1596 for both weight control and type 2 diabetes.
Deal structure and Novo’s strategy
Novo Nordisk will pay Hengrui Pharma $300 million upfront. Milestone payments could push the total to $2.6 billion. Novo gets exclusive rights to develop and sell HRS-1596 outside China. Hengrui keeps rights in mainland China, Hong Kong, Macau, and Taiwan. That’s according to a Reuters financial review. Novo plans to use its experience in oral peptide drugs to push HRS-1596 forward.
Novo faces pressure to keep its lead in metabolic disease. The once-weekly oral format could make life easier for patients. Daily pills and injections are still the norm. Novo said HRS-1596 "has potential for development as an oral drug administered once a week" and could "substantially reduce dosing frequency and improve convenience compared with current offerings." That’s a big promise. The market could shift if it works.
Competition and what’s known so far
HRS-1596 is still in Phase 1. No human safety or efficacy data are out yet. The drug is being tested in China for type 2 diabetes and weight management. Novo is spending big before seeing results. The stakes are high. The metabolic disease market is fierce. Other companies are also making early bets, as reported earlier by GenoMethods.
Novo’s licensing play is a risk. The company is counting on HRS-1596 to deliver weekly oral dosing and dual receptor action. If trials go well, Novo could tighten its grip on obesity and diabetes drugs. But the drug is still in early human testing. Everything depends on future trial results and regulatory steps. For now, Novo’s move raises the stakes. The race for next-generation metabolic drugs is wide open.
HRS-1596 is described as a Phase I-ready GLP-1R/GIPR dual agonist, and its claimed advantages in efficacy and safety have not yet been confirmed by late-stage clinical data.
